Food and Drug Administration

Food and Drug Administration

Pulmonary/Allergy Drugs Advisory Committee

January 17, 2002

Flovent Diskus (NDA# 20-822/S-004) and Advair Diskus (NDA# 21-077/S-003) as long-term maintenance therapy in patients with Chronic Obstructive Pulmonary Disease (COPD)

Briefing Information

Sponsor Presentation - GlaxoSmithKline

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

FLOVENT® DISKUS® (fluticasone propionate inhalation powder) NDA 20-833 pdf doc

ADVAIR™ DISKUS® (fluticasone propionate/salmeterol inhalation pwder) 100/50mcg, 250/5mcg and 500/50mcg NDA 21-077 pdf doc

Food and Drug Administration Backgrounders

FLOVENT® DISKUS® (fluticasone propionate inhalation powder) NDA 20-833 pdf doc

ADVAIR™ DISKUS® (fluticasone propionate/salmeterol inhalation pwder) 100/50mcg, 250/5mcg and 500/50mcg NDA 21-077 pdf doc